Fasting: Clinical Trials

7 trials for Fasting, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 2 completed, 1 active not recruiting, 1 recruiting. 7 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 17Unknown 3, Completed 2, Active not recruiting 1, Recruiting 1

Follow Fasting: new trials by email Literature Review of Fasting trials Research Report on Fasting

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Optimization of Basal Insulin During Ramadan Fasting in Type 2 Diabetic Patients: Comparison Between DAR Recommendations and the Carbohydrate Fasting Test & Metabolic and Inflammatory Consequences
Adjustment of insulin doses DAR, Adjustment of insulin doses CFT - Diabetes Mellitus, Type 2 Treated With Insulin, Fasting, Intermittent
Early Phase 1Active not recruitingUniversity Tunis El Manar1002025-02-152026-09-10
Time Restricted Eating in Sleep Apnea
Time restricted eating - Time Restricted Eating, Obstructive Sleep Apnea
Early Phase 1RecruitingUniversity of California, San Diego802024-01-052024-01-16
Pharmacokinetics of AUX-001 40mg Once-daily in Healthy Subjects Under Fasting and Fed Conditions
AUX-001 40mg once-daily - Chronic Stable Angina
Early Phase 1UnknownAuxilius Pharma sp.z.o.o.162023-11-272024-02-12
The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve)
Metyrapone 250 mg Oral Tablets, Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo 250 mg Tablets - Glucocorticoid Effect
Early Phase 1CompletedEleonora Seelig242023-05-152024-08-14
Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers
Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) - Healthy Volunteers, Fasting
Early Phase 1CompletedTAHO Pharmaceuticals Ltd.122022-12-052023-08-18
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
GC012F injection - Multiple Myeloma
Early Phase 1UnknownShanghai Changzheng Hospital152021-12-012021-09-22
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
GC012F injection - Multiple Myeloma
Early Phase 1UnknownShanghai Changzheng Hospital152020-01-162021-06-15

Narrower conditions

Intermittent Fasting (2)  ·  Lecithin Cholesterol Acyltransferase Deficiency (2)  ·  Multiple Myeloma (2)  ·  Angina, Stable (1)  ·  Diabetes Mellitus (1)  ·  Hyperglycemia (1)  ·  Hyperlipidemias (1)  ·  Metabolic Syndrome (1)  ·  Sleep Apnea Syndromes (1)  ·  Sleep Apnea, Obstructive (1)  ·  Starvation (1)  ·  Weight Loss (1)

Broader conditions

Behavior (7)  ·  Feeding Behavior (7)  ·  Nutritional and Metabolic Diseases (5)  ·  Metabolic Diseases (4)  ·  Cardiovascular Diseases (3)  ·  Dyslipidemias (3)  ·  Lipid Metabolism Disorders (3)  ·  Vascular Diseases (3)  ·  Blood Protein Disorders (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Glucose Metabolism Disorders (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)

Interventions

Hydrocortisone (1)  ·  Metyrapone (1)  ·  Tablets (1)  ·  apixaban (1)

Sponsors

Shanghai Changzheng Hospital (2)  ·  Auxilius Pharma sp.z.o.o. (1)  ·  Eleonora Seelig (1)  ·  TAHO Pharmaceuticals Ltd. (1)  ·  University Tunis El Manar (1)  ·  University of California, San Diego (1)

Countries

China (2)  ·  United States (2)  ·  Portugal (1)  ·  Switzerland (1)  ·  Tunisia (1)

Top investigators

Marlene Fonseca, MD (1)  ·  Omar Mesarwi, MD (1)  ·  Philip Mathew, M.D. (1)

NIH funding

2023 (1)